Piper Jaffray Companies Lowers Tetraphase Pharmaceuticals (TTPH) Price Target to $6.00

Tetraphase Pharmaceuticals (NASDAQ:TTPH) had its price objective reduced by equities research analysts at Piper Jaffray Companies to $6.00 in a research note issued on Thursday, The Fly reports. The brokerage currently has an “overweight” rating on the biopharmaceutical company’s stock. Piper Jaffray Companies’ price target suggests a potential upside of 145.90% from the company’s current price.

TTPH has been the subject of several other reports. B. Riley lifted their price target on Tetraphase Pharmaceuticals from $6.00 to $7.00 and gave the stock a “buy” rating in a report on Tuesday, August 28th. Needham & Company LLC reissued a “hold” rating on shares of Tetraphase Pharmaceuticals in a report on Friday, August 3rd. Zacks Investment Research cut Tetraphase Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, July 7th. WBB Securities raised Tetraphase Pharmaceuticals from a “speculative buy” rating to a “buy” rating and set a $7.00 price target for the company in a report on Thursday, September 6th. Finally, ValuEngine cut Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, July 30th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and seven have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $6.16.

NASDAQ:TTPH opened at $2.44 on Thursday. The company has a market cap of $145.89 million, a P/E ratio of -0.93 and a beta of 2.57. Tetraphase Pharmaceuticals has a 1-year low of $2.05 and a 1-year high of $7.29.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last released its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.36) by $0.18. The business had revenue of $11.58 million during the quarter, compared to analysts’ expectations of $2.23 million. Tetraphase Pharmaceuticals had a negative return on equity of 67.34% and a negative net margin of 421.64%. Analysts predict that Tetraphase Pharmaceuticals will post -1.38 earnings per share for the current year.

Institutional investors have recently bought and sold shares of the business. Flagship Harbor Advisors LLC bought a new position in Tetraphase Pharmaceuticals during the 2nd quarter worth $104,000. Canada Pension Plan Investment Board bought a new position in Tetraphase Pharmaceuticals during the 2nd quarter worth $179,000. UBS Group AG bought a new position in Tetraphase Pharmaceuticals during the 1st quarter worth $1,130,000. Royce & Associates LP bought a new position in Tetraphase Pharmaceuticals during the 2nd quarter worth $556,000. Finally, Dynamic Technology Lab Private Ltd increased its stake in Tetraphase Pharmaceuticals by 322.1% during the 1st quarter. Dynamic Technology Lab Private Ltd now owns 76,108 shares of the biopharmaceutical company’s stock worth $234,000 after acquiring an additional 58,079 shares during the period. Hedge funds and other institutional investors own 40.93% of the company’s stock.

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is eravacycline, a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections.

See Also: Book Value Per Share – BVPS

The Fly

Analyst Recommendations for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply